Opin vísindi

Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project

Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project


Title: Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project
Author: PSERENADE Team
Date: 2021-04-01
Language: English
Scope:
University/Institute: Landspitali - The National University Hospital of Iceland
Department: Faculty of Medicine
Clinical Laboratory Services, Diagnostics and Blood Bank
Series: Microorganisms; 9(4)
ISSN: 2076-2607
DOI: https://doi.org/10.3390/microorganisms9040738
Subject: Heilahimnubólga; Yfirlitsrannsókn; Yfirlitsrannsókn; Global; Meta-analysis; PCV impact; Pneumococcal meningitis; Serotype distribution; Microbiology; Microbiology (medical); Virology
URI: https://hdl.handle.net/20.500.11815/3202

Show full item record

Citation:

PSERENADE Team 2021 , ' Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project ' , Microorganisms , vol. 9 , no. 4 , 738 . https://doi.org/10.3390/microorganisms9040738

Abstract:

Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5-7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.

Description:

Funding text The PSERENADE project is funded by the Bill and Melinda Gates Foundation as part of the World Health Organization Pneumococcal Vaccines Technical Coordination Project, grant number INV-010429/OPP1189065. Publisher Copyright: © 2021 by the authors.

Files in this item

This item appears in the following Collection(s)